Otsuka Holdings Co., Ltd.
http://www.otsuka.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Otsuka Holdings Co., Ltd.
First Digital Therapeutic App Filed For Approval In Expanding Japan ADHD Market
A pioneering approval filing for a therapeutic app by Shionogi is set to herald expansion of ADHD therapies beyond the pill in Japan, along with growth in the pediatric segment for the disorder.
Remibrutinib REMIXes The Itch Record
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Otsuka Counts The Cost Of Alzheimer’s Agitation Fail
The group will take a $770m impairment charge thanks to the Phase III failure of AVP-786 – but further trials continue.
Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance
Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Alamo Pharmaceuticals, LLC
- Astex Pharmaceuticals, Inc.
- Avanir Pharmaceuticals, Inc.
- Daiya Foods Inc.
- Diatranz Otsuka Limited
- JIMRO Co., Ltd.
- Korea Otsuka Pharmaceutical Co., Ltd.
- Mitsui & Co., Ltd
- Montigen Pharmaceuticals
- Neurovance, Inc.
- Otsuka Australia Pharmaceutical Pty Ltd
- Otsuka Pharmaceutical Factory, Inc.
- Otsuka Medical Devices Co., Ltd.
- Otsuka Pharmaceutical Co., Ltd
- Otsuka Pharmaceutical India Private Limited
- ReCor Medical, Inc.
- Singapore Otsuka Pharmaceutical Co., Ltd.
- SuperGen, Inc.
- Taiwan Otsuka Pharmaceutical Co., Ltd.
- Taiho Pharmaceutical Co., Ltd.
- Taiho Pharma Canada, Inc.
- Visterra Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice